LDL Reduction: How Low Should We Go and is It Safe?

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2008 Oct 28

PMID 18950559

Citations 1

Authors

Jennifer G Robinson

Affiliations

Soon will be listed here.

Abstract

High-dose statin therapy or combination statin treatment is necessary for most patients to achieve aggressive low-density lipoprotein cholesterol goals. Adding ezetimibe or bile acid sequestrants appears unlikely to increase the risk of myopathy. Although the combination of niacin or fenofibrate with moderate-dose statins appears to be reasonably safe, the safety of combination with high-dose statins has yet to be determined. To enhance patient outcomes, attention must be paid to characteristics that predict muscle and hepatic statin toxicity when considering using high-dose statin or combination statin therapy.

Citing Articles

Fenofibrate Interferes with the Diapedesis of Lung Adenocarcinoma Cells through the Interference with Cx43/EGF-Dependent Intercellular Signaling.

Piwowarczyk K, Kwiecien E, Sosniak J, Zimolag E, Guzik E, Sroka J Cancers (Basel). 2018; 10(10).

PMID: 30274176 PMC: 6210471. DOI: 10.3390/cancers10100363.

References

Knopp R, Tsunehara C, Retzlaff B, Fish B, Nguyen H, Anderson S . Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism. 2006; 55(12):1697-703. DOI: 10.1016/j.metabol.2006.08.013. View

Johnson H, Douglas P, Srinivasan S, Bond M, Tang R, Li S . Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study. Stroke. 2007; 38(3):900-5. DOI: 10.1161/01.STR.0000258003.31194.0a. View

Robinson J, Stone N . Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol. 2006; 98(10):1405-8. DOI: 10.1016/j.amjcard.2006.06.039. View

Ballantyne C, Davidson M, McKenney J, Keller L, Bajorunas D, Karas R . Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008; 101(10):1428-36. DOI: 10.1016/j.amjcard.2008.02.092. View

Law M, Wald N, Morris J . Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003; 7(31):1-94. DOI: 10.3310/hta7310. View

Davidson M, Maccubbin D, Stepanavage M, Strony J, Musliner T . Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol. 2006; 97(2):223-8. DOI: 10.1016/j.amjcard.2005.08.038. View

Durrington P, Tuomilehto J, Hamann A, Kallend D, Smith K . Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. 2004; 64(2):137-51. DOI: 10.1016/j.diabres.2003.11.012. View

Davidson M, Clark J, Glass L, Kanumalla A . Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006; 97(8A):32C-43C. DOI: 10.1016/j.amjcard.2005.12.008. View

Ford E, Ajani U, Croft J, Critchley J, Labarthe D, Kottke T . Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356(23):2388-98. DOI: 10.1056/NEJMsa053935. View

10.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

11.

Smith Jr S, Allen J, Blair S, Bonow R, Brass L, Fonarow G . AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113(19):2363-72. DOI: 10.1161/CIRCULATIONAHA.106.174516. View

12.

Farnier M, Roth E, Gil-Extremera B, Mendez G, Macdonell G, Hamlin C . Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J. 2007; 153(2):335.e1-8. DOI: 10.1016/j.ahj.2006.10.031. View

13.

Barter P, Caulfield M, Eriksson M, Grundy S, Kastelein J, Komajda M . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-22. DOI: 10.1056/NEJMoa0706628. View

14.

Silva M, Swanson A, Gandhi P, Tataronis G . Statin-related adverse events: a meta-analysis. Clin Ther. 2006; 28(1):26-35. DOI: 10.1016/j.clinthera.2006.01.005. View

15.

Jacobson T, Armani A, McKenney J, Guyton J . Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol. 2007; 99(6A):47C-55C. DOI: 10.1016/j.amjcard.2006.11.022. View

16.

Kastelein J, van der Steeg W, Holme I, Gaffney M, Cater N, Barter P . Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008; 117(23):3002-9. DOI: 10.1161/CIRCULATIONAHA.107.713438. View

17.

Kasiske B, Wanner C, ONeill W . An assessment of statin safety by nephrologists. Am J Cardiol. 2006; 97(8A):82C-85C. DOI: 10.1016/j.amjcard.2005.12.015. View

18.

Davidson M, Armani A, McKenney J, Jacobson T . Safety considerations with fibrate therapy. Am J Cardiol. 2007; 99(6A):3C-18C. DOI: 10.1016/j.amjcard.2006.11.016. View

19.

LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View

20.

van Wissen S, Smilde T, Trip M, Stalenhoef A, Kastelein J . Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol. 2005; 95(2):264-6. DOI: 10.1016/j.amjcard.2004.09.015. View